TORONTO — Radiant Biotherapeutics has appointed Deborah Geraghty, Ph.D., as its new President and CEO as the company prepares to advance its lead immuno-oncology candidate into clinical trials. The leadership changes come as part of a broader effort to strengthen the company’s executive team following a recent $35 million Series A financing round.
Stefan Larson, Ph.D., a venture investor and biotech entrepreneur, has been named Chair of the Board, while Ingmar Bruns, M.D., Ph.D., has joined as a new board member. Both bring extensive experience in oncology drug development and biotech company building.
Geraghty previously served as CEO of Anokion SA, a clinical-stage biotech focused on autoimmune diseases, and has held senior roles at Dimension Therapeutics, Cydan Development, Aileron Therapeutics, and Infinity Pharmaceuticals. Her background spans corporate strategy, IPO execution, and early-stage development.
“What drew me to this role are the compelling preclinical data based on Radiant’s strong scientific foundation,” said Geraghty. “The opportunity to advance breakthrough therapies for cancer and autoimmune diseases is deeply motivating.”
Larson, a venture partner at Sectoral Asset Management and former founding CEO of Northern Biologics, will help guide the company through its next stage of growth. “Dr. Geraghty brings a proven track record of building and transforming biotech companies. She’s the ideal leader as we move toward the clinic,” Larson said.
Bruns, currently Chief Medical Officer at Zentalis, brings two decades of hematology and oncology expertise, including leadership roles at Pfizer, Trillium Therapeutics, and Bayer Pharmaceuticals.
Radiant’s proprietary Multabody™ platform is designed to develop multi-specific antibodies that can target multiple disease pathways simultaneously. The company’s lead candidate, a 4-1BB agonist, is expected to enter clinical testing in the near future.
The leadership transition also marks the departure of Arthur Fratamico, who served as CEO for four years and helped lay the company’s foundation. Board member Dion Madsen acknowledged Fratamico’s contributions and said the board is focused on supporting Radiant’s transition to a clinical-stage company. (Source: IANS)
